NVSEF Quote, Financials, Valuation and Earnings

Addex Therapeutics has a net margin of 20.79% compared to Novartis AG's net margin of -2841.85%. Novartis AG's return on equity of 27.64% beat Addex Therapeutics's return on equity of 91.08%.

Novartis AG has a consensus price target of --, signalling downside risk potential of -28.82%. On the other hand Addex Therapeutics has an analysts' consensus of $30.00 which suggests that it could grow by 294.74%. Given that Addex Therapeutics has higher upside potential than Novartis AG, analysts believe Addex Therapeutics is more attractive than Novartis AG.

Novartis AG has a beta of 0.515, which suggesting that the stock is 48.457% less volatile than S&P 500. In comparison Addex Therapeutics has a beta of 1.757, suggesting its more volatile than the S&P 500 by 75.723%.

Novartis AG has a quarterly dividend of $3.98 per share corresponding to a yield of 3.41%. Addex Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novartis AG pays 63.85% of its earnings as a dividend. Addex Therapeutics pays out -- of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novartis AG quarterly revenues are $13.6B, which are larger than Addex Therapeutics quarterly revenues of $62.3K. Novartis AG's net income of $2.8B is higher than Addex Therapeutics's net income of -$1.8M. Notably, Novartis AG's price-to-earnings ratio is 19.83x while Addex Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 4.59x versus 14.04x for Addex Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

CRISPR Therapeutics AG has a net margin of 20.79% compared to Novartis AG's net margin of -106.6%. Novartis AG's return on equity of 27.64% beat CRISPR Therapeutics AG's return on equity of -18.65%.

Novartis AG has a consensus price target of --, signalling downside risk potential of -28.82%. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $83.60 which suggests that it could grow by 102.81%. Given that CRISPR Therapeutics AG has higher upside potential than Novartis AG, analysts believe CRISPR Therapeutics AG is more attractive than Novartis AG.

Novartis AG has a beta of 0.515, which suggesting that the stock is 48.457% less volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.767, suggesting its more volatile than the S&P 500 by 76.677%.

Novartis AG has a quarterly dividend of $3.98 per share corresponding to a yield of 3.41%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novartis AG pays 63.85% of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novartis AG quarterly revenues are $13.6B, which are larger than CRISPR Therapeutics AG quarterly revenues of $35M. Novartis AG's net income of $2.8B is higher than CRISPR Therapeutics AG's net income of -$37.3M. Notably, Novartis AG's price-to-earnings ratio is 19.83x while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 4.59x versus -- for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.

Roche Holding AG has a net margin of 20.79% compared to Novartis AG's net margin of --. Novartis AG's return on equity of 27.64% beat Roche Holding AG's return on equity of 23.8%.

Novartis AG has a consensus price target of --, signalling downside risk potential of -28.82%. On the other hand Roche Holding AG has an analysts' consensus of $46.29 which suggests that it could grow by 5.92%. Given that Roche Holding AG has higher upside potential than Novartis AG, analysts believe Roche Holding AG is more attractive than Novartis AG.

Novartis AG has a beta of 0.515, which suggesting that the stock is 48.457% less volatile than S&P 500. In comparison Roche Holding AG has a beta of 0.404, suggesting its less volatile than the S&P 500 by 59.628%.

Novartis AG has a quarterly dividend of $3.98 per share corresponding to a yield of 3.41%. Roche Holding AG offers a yield of 0% to investors and pays a quarterly dividend of $1.35 per share. Novartis AG pays 63.85% of its earnings as a dividend. Roche Holding AG pays out 92.43% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Novartis AG quarterly revenues are $13.6B, which are larger than Roche Holding AG quarterly revenues of --. Novartis AG's net income of $2.8B is higher than Roche Holding AG's net income of --. Notably, Novartis AG's price-to-earnings ratio is 19.83x while Roche Holding AG's PE ratio is 30.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 4.59x versus 4.00x for Roche Holding AG. Usually stocks with elevated PS ratios are considered overvalued.